Your session is about to expire
← Back to Search
Ponesimod 10 mg for Multiple Sclerosis
Study Summary
This trial will study the long-term effects of ponesimod, a drug used to treat relapsing-remitting multiple sclerosis.
- Multiple Sclerosis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Ponesimod 10 mg
- Group 2: Ponesimod 40 mg
- Group 3: Ponesimod 20 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research project require participants to be over the age of 20?
"The age range for this study is 18-55, as outlined in the eligibility requirements."
What is the estimated sample size for this trial?
"This trial is not enrolling patients at the moment, although it was accepting them in the past. The last date that information on the trial was updated was November 8th, 2022. There are currently 564 other trials for multiple sclerosis and 3 studies involving Ponesimod 10 mg that are looking for participants."
Who meets the eligibility requirements for this clinical trial?
"This trial, which is looking for 353 participants, is only open to patients that have multiple sclerosis and are between 18-55 years old."
Are there any other scientific studies that have used Ponesimod 10 mg?
"Ponesimod 10 mg is being trialed in 3 active studies, one of which has reached Phase 3. Many of the clinical trials for Ponesimod 10 mg are based in Chernihiv and Florida, with a total of 252 locations running tests."
Has Ponesimod 10 mg received FDA sanctioning?
"Ponesimod 10 mg is currently in Phase 2 of clinical trials. While there is promising safety data, there is no evidence yet that the medication is effective."
Can patients still sign up for this research project?
"Unfortunately, this particular study is not presently looking for new patients. Although the trial was most recently updated on November 8th 2022, it is not currently recruiting. However, there are 567 other trials that might be a better match for you and which are actively searching for participants right now."
Is this trial available in many locations around the city?
"There are a total of 17 clinical trial sites for this study. The locations include Venice, Kansas City and Latham. There may be other centres near you, so it is advised that patients enroll at the closest location to minimize travel requirements."
What is the historical context of this clinical trial?
"Ponesimod 10 mg has been studied since 2010 when it was first trialled by Actelion. The drug progressed to Phase 2 after the successful initial study of 353 in 2010. Ponesimod 10 mg is currently being trialled in 31 countries and 52 cities."
Share this study with friends
Copy Link
Messenger